Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney

D. Reglodi, P. Kiss, Gabriella Horvath, A. Lubics, Eszter Laszlo, A. Tamás, B. Rácz, Peter Szakaly

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread neuropeptide with diverse effects in the nervous system and peripheral organs. One of the most well-studied effects of PACAP is its cytoprotective action, against different harmful stimuli in a wide variety of cells and tissues. PACAP occurs in the urinary system, from the kidney to the lower urinary tract. The present review focuses on the nephroprotective effects of PACAP and summarizes data obtained regarding the protective effects of PACAP in different models of kidney pathologies. In vitro data show that PACAP protects tubular cells against oxidative stress, myeloma light chain, cisplatin, cyclosporine-A and hypoxia. In vivo data provide evidence for its protective effects in ischemia/reperfusion, cisplatin, cyclosporine-A, myeloma kidney injury, diabetic nephropathy and gentamicin-induced kidney damage. Results accumulated on the renoprotective effects of PACAP suggest that PACAP is an emerging candidate for treatment of human kidney pathologies.

Original languageEnglish
Pages (from-to)61-70
Number of pages10
JournalNeuropeptides
Volume46
Issue number2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Kidney
Cisplatin
Cyclosporine
Pathology
Peripheral Nervous System
Diabetic Nephropathies
Gentamicins
Neuropeptides
Urinary Tract
Reperfusion
Oxidative Stress
Ischemia
Light
Wounds and Injuries

Keywords

  • Cisplatin
  • Cyclosporine-A
  • Ischemia
  • Kidney
  • Myeloma
  • Oxidative stress

ASJC Scopus subject areas

  • Endocrinology
  • Neurology
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems

Cite this

Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. / Reglodi, D.; Kiss, P.; Horvath, Gabriella; Lubics, A.; Laszlo, Eszter; Tamás, A.; Rácz, B.; Szakaly, Peter.

In: Neuropeptides, Vol. 46, No. 2, 04.2012, p. 61-70.

Research output: Contribution to journalArticle

@article{7b1e690dc2594d958fee25cc3cf9cce4,
title = "Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney",
abstract = "Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread neuropeptide with diverse effects in the nervous system and peripheral organs. One of the most well-studied effects of PACAP is its cytoprotective action, against different harmful stimuli in a wide variety of cells and tissues. PACAP occurs in the urinary system, from the kidney to the lower urinary tract. The present review focuses on the nephroprotective effects of PACAP and summarizes data obtained regarding the protective effects of PACAP in different models of kidney pathologies. In vitro data show that PACAP protects tubular cells against oxidative stress, myeloma light chain, cisplatin, cyclosporine-A and hypoxia. In vivo data provide evidence for its protective effects in ischemia/reperfusion, cisplatin, cyclosporine-A, myeloma kidney injury, diabetic nephropathy and gentamicin-induced kidney damage. Results accumulated on the renoprotective effects of PACAP suggest that PACAP is an emerging candidate for treatment of human kidney pathologies.",
keywords = "Cisplatin, Cyclosporine-A, Ischemia, Kidney, Myeloma, Oxidative stress",
author = "D. Reglodi and P. Kiss and Gabriella Horvath and A. Lubics and Eszter Laszlo and A. Tam{\'a}s and B. R{\'a}cz and Peter Szakaly",
year = "2012",
month = "4",
doi = "10.1016/j.npep.2011.05.001",
language = "English",
volume = "46",
pages = "61--70",
journal = "Neuropeptides",
issn = "0143-4179",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney

AU - Reglodi, D.

AU - Kiss, P.

AU - Horvath, Gabriella

AU - Lubics, A.

AU - Laszlo, Eszter

AU - Tamás, A.

AU - Rácz, B.

AU - Szakaly, Peter

PY - 2012/4

Y1 - 2012/4

N2 - Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread neuropeptide with diverse effects in the nervous system and peripheral organs. One of the most well-studied effects of PACAP is its cytoprotective action, against different harmful stimuli in a wide variety of cells and tissues. PACAP occurs in the urinary system, from the kidney to the lower urinary tract. The present review focuses on the nephroprotective effects of PACAP and summarizes data obtained regarding the protective effects of PACAP in different models of kidney pathologies. In vitro data show that PACAP protects tubular cells against oxidative stress, myeloma light chain, cisplatin, cyclosporine-A and hypoxia. In vivo data provide evidence for its protective effects in ischemia/reperfusion, cisplatin, cyclosporine-A, myeloma kidney injury, diabetic nephropathy and gentamicin-induced kidney damage. Results accumulated on the renoprotective effects of PACAP suggest that PACAP is an emerging candidate for treatment of human kidney pathologies.

AB - Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread neuropeptide with diverse effects in the nervous system and peripheral organs. One of the most well-studied effects of PACAP is its cytoprotective action, against different harmful stimuli in a wide variety of cells and tissues. PACAP occurs in the urinary system, from the kidney to the lower urinary tract. The present review focuses on the nephroprotective effects of PACAP and summarizes data obtained regarding the protective effects of PACAP in different models of kidney pathologies. In vitro data show that PACAP protects tubular cells against oxidative stress, myeloma light chain, cisplatin, cyclosporine-A and hypoxia. In vivo data provide evidence for its protective effects in ischemia/reperfusion, cisplatin, cyclosporine-A, myeloma kidney injury, diabetic nephropathy and gentamicin-induced kidney damage. Results accumulated on the renoprotective effects of PACAP suggest that PACAP is an emerging candidate for treatment of human kidney pathologies.

KW - Cisplatin

KW - Cyclosporine-A

KW - Ischemia

KW - Kidney

KW - Myeloma

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84858295185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858295185&partnerID=8YFLogxK

U2 - 10.1016/j.npep.2011.05.001

DO - 10.1016/j.npep.2011.05.001

M3 - Article

C2 - 21621841

AN - SCOPUS:84858295185

VL - 46

SP - 61

EP - 70

JO - Neuropeptides

JF - Neuropeptides

SN - 0143-4179

IS - 2

ER -